Safety and Efficacy of Cocktail Periarticular Injection in Simultaneous Total Knee Arthroplasty

Safety and Efficacy of Cocktail Periarticular Injection for Pain Management in Simultaneous Bilateral Total Knee Arthroplasty- A Prospective, Randomized Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02270437

Enrollment

Registered

2014-10-21

Start date

2014-06-30

Completion date

2015-08-31

Last updated

2015-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

total knee arthroplasty, cocktail analgesia, morphine consumption

Brief summary

We investigated the safety and efficacy of the bilateral periarticular cocktail injection at a reduced dosage in patients undergoing simultaneous bilateral total knee arthroplasty.

Detailed description

It is hypothesized that intraoperative periarticular injection with cocktail analgesics can reduce postoperative parenteral narcotics use and improve patient satisfaction following total knee arthroplasty. A prospective, randomized trial is conducted to testify the hypothesis above by recruiting patients who go through simultaneous bilateral TKA and observing their postoperative analgesic consumption, visual analog scores and functional recovery. Potential side-effects of the multimodal drugs is also under observation.

Interventions

DRUGropivacaine, fentanyl, adrenaline

The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

No minimum to 80 Years

Healthy volunteers

Inclusion criteria

* patients with tricompartmental knee disease undergoing simultaneous bilateral TKA

Exclusion criteria

* diabetes mellitus * neuromuscular deficit * a known allergy to one of the drugs being injected * a history of cardiac disease or arrhythmia requiring special monitoring

Design outcomes

Primary

Measure	Time frame
To evaluate the Morphine consumption and PCIA duration	12 hours to 3 days after the surgery

Secondary

Measure	Time frame
To evaluate the visual analog scale (VAS) in each group patients underwent total knee arthroplasty	4 hours to 5 days after the surgery
Function recovery evaluation for patients received surgery	1, 3 and 5 days after the surgery

Other

Measure	Time frame
Testing of body temperature,routine blood examination	hospital admission and 1, 3, 5 days after the surgery

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026